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Abstract
Background: The ClinicalTrials.gov registry provides information regarding characteristics of past, current, and planned
clinical studies to patients, clinicians, and researchers; in addition, registry data are available for bulk download. However,
issues related to data structure, nomenclature, and changes in data collection over time present challenges to the
aggregate analysis and interpretation of these data in general and to the analysis of trials according to clinical specialty in
particular. Improving usability of these data could enhance the utility of ClinicalTrials.gov as a research resource.
Methods/Principal Results: The purpose of our project was twofold. First, we sought to extend the usability of
ClinicalTrials.gov for research purposes by developing a database for aggregate analysis of ClinicalTrials.gov (AACT) that
contains data from the 96,346 clinical trials registered as of September 27, 2010. Second, we developed and validated a
methodology for annotating studies by clinical specialty, using a custom taxonomy employing Medical Subject Heading
(MeSH) terms applied by an NLM algorithm, as well as MeSH terms and other disease condition terms provided by study
sponsors. Clinical specialists reviewed and annotated MeSH and non-MeSH disease condition terms, and an algorithm was
created to classify studies into clinical specialties based on both MeSH and non-MeSH annotations. False positives and false
negatives were evaluated by comparing algorithmic classification with manual classification for three specialties.
Conclusions/Significance: The resulting AACT database features study design attributes parsed into discrete fields,
integrated metadata, and an integrated MeSH thesaurus, and is available for download as Oracle extracts (.dmp file and text
format). This publicly-accessible dataset will facilitate analysis of studies and permit detailed characterization and analysis of
the U.S. clinical trials enterprise as a whole. In addition, the methodology we present for creating specialty datasets may
facilitate other efforts to analyze studies by specialty groups.
Citation: Tasneem A, Aberle L, Ananth H, Chakraborty S, Chiswell K, et al. (2012) The Database for Aggregate Analysis of ClinicalTrials.gov (AACT) and Subsequent
Regrouping by Clinical Specialty. PLoS ONE 7(3): e33677. doi:10.1371/journal.pone.0033677
Editor: Joel Joseph Gagnier, University of Michigan, United States of America
Received October 14, 2011; Accepted February 14, 2012; Published March 16, 2012
Copyright:  2012 Tasneem et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Financial support for this work was provided by cooperative agreement U19 FD003800 awarded by the U.S. Food and Drug Administration to Duke
University in support of the Clinical Trials Transformation Initiative. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: asba.tasneem@duke.edu
Introduction
ClinicalTrials.gov (www.ClinicalTrials.gov) is a registry of
human clinical research studies. It is hosted by the National
Library of Medicine (NLM) at the National Institutes of Health
(NIH) in collaboration with the U.S. Food and Drug Administra-
tion (FDA). As mandated by federal law [1], ClinicalTrials.gov
provides a central resource for information about clinical trials; in
addition, it increases the public visibility of such research. The
registry currently contains over 100,000 research studies conduct-
ed in more than 170 countries and is widely used both by medical
professionals and the public. New research studies are being
submitted to the registry by their respective sponsors (or sponsors’
designees) at a rate of approximately 350 per week [2]. Due to
legislative [1] and institutional [3] requirements enacted in the
latter half of the previous decade, compliance with registry
obligations is assumed to be high for U.S. drug and device trials,
and the consistency, quality, and maintenance of registry data
have improved with increased use [4]. However, the registry has
not been optimized for the analysis of aggregate data, and a
systematic effort to create and maintain a database for this purpose
has not previously been undertaken.
In November 2007, the FDA and Duke University announced
the formation of a public-private partnership to improve the
quality and efficiency of clinical trials. This collaboration of more
than 60 organizations and government agencies was convened by
Duke University under a memorandum of understanding with
FDA, and is now known as the Clinical Trials Transformation
Initiative (CTTI) [5]. CTTI leaders recognized that Clinical-
Trials.gov represented a promising source for benchmarking the
state of the clinical trials enterprise, as the registry contains studies
from the full range of sponsoring organizations. Increasing the
usability of ClinicalTrials.gov data may therefore facilitate
systematic evaluation of clinical studies aimed at building the
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e33677knowledge base needed to inform medical practice and preven-
tion.
As data have accumulated in ClinicalTrials.gov, users have
increasingly sought capabilities that would allow aggregated
descriptive characterization of the national research portfolio;
however, access and data usability issues, including data format
and design, present obstacles. A number of related initiatives,
including the Ontology of Clinical Research (OCRe) [6], Human
Studies Database (HSDB) [7], CDISC Protocol Representation
Model [8], and LinkedCT [9] projects, are addressing ontological
annotations, large-scale data mining, data representation format,
and external association of these data, respectively. The results of
this project are complementary to these initiatives and are
expected to collectively advance this area of study as a whole.
In this article, we report on CTTI’s efforts to prepare and
maintain a publicly accessible analysis dataset derived from
ClinicalTrials.gov content—the database for aggregate analysis
of ClinicalTrials.gov (AACT). We also discuss efforts to extend the
utility of the analysis dataset by means of an associated clinical
specialty taxonomy designed to support research policy analyses.
Methods
1. Creation of the AACT
Key design features of AACT include 1) the capacity to extend
the dataset by parsing existing data; 2) linking to additional data
resources, such as the Medical Subject Headings (MeSH)
thesaurus; and 3) integrated metadata. A framework for extensions
allows entire studies or individual fields to be associated with new
data resources while preserving provenance. In addition, the
integrated data dictionary developed for this project facilitates
browsing and analysis of ClinicalTrials.gov and AACT metadata.
Finally, the database incorporates a flexible design that can
accommodate future developments, such as coding biospecimen
type, sponsors, and OCRe annotations. Figure 1 shows key
enhancements achieved by building the AACT.
Figure 1. A schematic representation of the database for Aggregate Analysis of ClinicalTrials.Gov (AACT) with its key
enhancements.
doi:10.1371/journal.pone.0033677.g001
Database for Aggregate Analysis of CT.gov
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studies was downloaded from ClinicalTrials.gov in XML format
on September 27, 2010. We chose ClinicalTrials.gov for our study
because it is the largest database of its kind and because it covers
the full range of clinical conditions, includes a broad group of trial
sponsors [10], and has a regulatory mandate [1]. The date of
download was chosen to coincide with the anniversary of the
enactment of the FDA Amendments Act (FDAAA) 3 years earlier,
which mandated the registration of certain trials of FDA-regulated
drugs, biologics, and devices [1].
We downloaded the 2010 MeSH thesaurus (http://www.nlm.
nih.gov/mesh/2010/download/termscon.html) and merged it
with the AACT database, where it was used as a lookup table to
locate corresponding tree numbers, referred to as MeSH IDs, for all
MeSH terms associated with each clinical trial in ClinicalTrials.
gov. Persons or organizations who submit studies to the registry
are requested to provide the condition and keyword data elements as
MeSH terms.
1.2. Data Model. ClinicalTrials.gov data element definitions,
xsd specifications for registry data submission, and downloaded
study XML files were used to represent data specifications for the
downloaded data. A physical data model was designed using
Enterprise Architect (Sparx Systems Pty Ltd, Creswick, Victoria,
Australia); this model depicted data tables and their data columns,
as well as relationships between and among tables. An optimal
structure was achieved through normalization, which was used to
organize data efficiently, eliminate redundancy, and ensure logical
data dependencies by storing only related data within a given table
[11]. The database (Figure 2) was normalized to the Second
Normal Form (2NF), a set of criteria designed to prevent logical
inconsistencies while reducing data redundancy [12].
We assigned data type and length of data elements based on
patterns observed for each data element in the downloaded XML
files. Whenever possible, we followed guidelines provided in
ClinicalTrials.gov’s draft Protocol Data Element Definitions [13]
when assigning lengths to given data elements. Data were housed
in Oracle RDBMS, version 11.1 g (Oracle Corporation, Redwood
Shores, California, USA). Enterprise Architect 7.1 was used for
database design and additional transformation rules were
documented as extract-transform-load (ETL) specifications. PL/
Figure 2. High-level Entity-Relationship Diagram (ERD) for AACT.
doi:10.1371/journal.pone.0033677.g002
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read the input XML files and load the data into the designed
tables appropriately were developed. Quality control and
operational support processes were developed using standard
SQL queries through Toad for Data Analysts (Quest Software,
Aliso Viejo, CA, USA) and Cognos ReportNet (CRN) (IBM
Corporation, Armonk, NY, USA). We extended the core data
model to accommodate both data management and data curation
purposes. Error log tables and indexes were created for testing,
debugging, and performance enhancement. Manual user accep-
tance testing was performed by randomly selecting five studies per
data element (from a total of 109 data elements) from the AACT
database. The values associated with each data element were
tested for correctness and completeness by comparing them with
the original source data from downloaded XML files. We also
created integrated data dictionary tables as reference tables
holding explicit data element definitions and system metadata
(Tables S1 and S2).
During the course of database development, the NLM made
several new data elements available for public download, some of
which included information about the FDA (e.g., Section 801
clinical trials, studies with FDA-regulated interventions, and
expanded-access studies). In addition to these, MeSH condition
and intervention terms generated by the NLM algorithm were also
made available for public download.
In XML files downloaded from ClinicalTrials.gov, the single
data element Study Design contains a string of concatenated values
for various different components of a study design, such as primary
purpose, interventional model, observational model, allocation,
endpoint classification, time perspective, and masking. While this
format is well-suited for supporting information retrieval, it does
not readily accommodate aggregate data analysis of the compo-
nents within the Study Design data element. For this reason, data
from Study Design was parsed into its components and stored in a
separate table called DESIGNS. Additional data elements (Design
Name and Design Value) were created to store all components of
study design and their respective enumerated values. Values
related to masking/blinding (e.g., Single; Double-Blind) were further
parsed into their components, along with the list of corresponding
masking subjects (Participant, Investigator, Outcome Assessor, and
Caregiver).
Several challenges were encountered while loading the
database, including foreign characters embedded in XML files
Table 1. Escape characters and replacements.
Escape character Replacement
’’
""
&&
" .
,,
doi:10.1371/journal.pone.0033677.t001
Figure 3. Percentage of interventional studies with complete data by registration year for selected data elements.
doi:10.1371/journal.pone.0033677.g003
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character references (see Table 1 for examples).
Other circumstances that prompted several database design
iterations included the facts that the maximum length for each
data element noted by ClinicalTrials.gov’s May 2010 Protocol
Data Element Definitions document was not always consistent
with the complete dataset, and one-to-one or one-to-many
relationships between or among data elements were not obvious
in the XML data type definition from ClinicalTrials.gov.
1.3. Quality Assessment. Of the 96,346 studies downloaded
from ClinicalTrials.gov in September 2010, a total of 79,413
(82.4%) were interventional (i.e., a study in which an investigator
following a protocol assigns research participants to receive
specific interventions, as opposed to an observational study),
Figure 4. An overview of methodology and process of developing clinical specialty datasets. The INTERVENTIONS, CONDITIONS, and
KEYWORDS tables consist of disease condition terms provided by data submitters that include both MeSH and non-MeSH terms. The
INTERVENTION_BROWSE and CONDITION_BROWSE tables are populated by MeSH terms generated by NLM algorithm (a) Process illustrating how
MeSH terms are created in ClinicalTrials.gov. Tables and data shown here does not represent entire ClinicalTrials.gov database (b) Process illustrating
the annotation and validation of disease conditions (c) Process illustrating the creation of specialty datasets.
doi:10.1371/journal.pone.0033677.g004
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access, and 320 had no information about the study type. We
analyzed selected data elements in interventional studies for
completeness of data (e.g., a null value in the data element) and
observed a trend toward increasing completeness of data over
time. This trend appears to have been notably affected by two
milestones in the history of ClinicalTrials.gov. In September 2004,
the International Council of Medical Journal Editors (ICMJE)
published a policy requiring registration of interventional trials as
a condition of publication [3]. The ICMJE requirements took
effect in September 2005, which may account for the increase in
completeness for some data elements in 2005 (Figure 3).
In September 2007, the FDAAA [1] made the registration of
interventional studies mandatory. This requirement took effect in
December 2007 and may further account for increases in the
completeness of data elements in the ClinicalTrials.gov dataset. In
Figure 3, the data elements ‘‘data monitoring committee’’ and
‘‘number of arms’’ were not available at the time that earlier
studies were registered. It is important to note that the presence of
these data elements for studies pre-dating December 2007 reflect
later updates performed by data providers.
1.4. Changes in ClinicalTrials.gov’s Protocol Data
Element Definitions. The ClinicalTrials.gov Protocol Data
Element Definitions (PDED) have evolved since the database was
first launched. Although references containing individual protocol
data element definitions are provided for submitters with each
release of the definitions document, there is no document that
tracks changes for all data elements for review as data
specifications. These include changing enumerated values for a
data element, revising a data element definition, making a
particular data element publicly available, introducing a new
data element, and entirely deleting a data element. However, more
rigorous submission rules imposed by mandating organizations
(e.g., NLM, FDA), such as those required by the FDAAA and
ClinicalTrials.gov, appear to have had the greatest impact on the
completeness of data.
Changes to a data element play a significant role in the analysis
of study data. As we examined each data element’s history, we
noted that between September 2004 and July 2005 (a period
spanning 3 releases of the PDED), and again in December 2007,
the data element requirements were not documented in the
definitions document. Other inconsistencies were also noted and
later confirmed (Personal communication, Dr. Deborah Zarin and
Mr. Nicholas Ide, February 18, 2011).
1.5. A Public Resource. The AACT can be downloaded as
Oracle extracts (.dmp file and text format output; available at
https://www.trialstransformation.org/projects/improving-the-public-
interface-for-use-of-aggregate-data-in-clinicaltrials.gov/aact-database-
for-aggregate-analysis-of-clinicaltrials.gov). Additional documents are
available to assist users in interpreting the data. The high-level data
dictionary and a comprehensive data dictionary noted previously are
included in the dataset file. The comprehensive data dictionary
contains seven sections: 1) currentv a r i a b l e s ,2 )e n u m e r a t i o n s ,3 )
constraints, 4) record counts, 5) database schema, 6) comprehensive
change history, and 7) variable history dates. This document provides
definitions, derivation of terms, data model structure and references,
NLM and FDAAA requirements, and historical information for each
data element in ClinicalTrials.gov to facilitate understanding of when
variables were added, modified, or discontinued. The high-level data
dictionary provides a summary view of the variables contained in the
AACT database.
2. A Methodology to Regroup Studies in
ClinicalTrials.Gov by Specialty
ClinicalTrials.gov contains studies from multiple clinical
domains. While the AACT database facilitates the aggregate
analysis of the entire dataset, it does not in itself support analysis
within specific specialty domains. We therefore developed a
methodology to re-group studies from ClinicalTrials.gov by
clinical specialties as designated by the Department of Health
and Human Services [14]. In doing so, we relied on MeSH
condition terms and free-text disease condition terms associated
with each study in the ClinicalTrials.gov database—a method
that can be used to develop other specialized datasets for
analysis.
2.1. Use of MeSH Terminology in the ClinicalTrials.gov
Database. Data submitters (study sponsors or their designees)
are requested to provide Condition and Keywords data as MeSH
terms when registering a study. Additionally, an NLM algorithm
Table 2. MeSH Subject Headings, 2010—Diseases.
Bacterial Infections and Mycoses [C01]
Virus Diseases [C02]
Parasitic Diseases [C03]
Neoplasms [C04]
Musculoskeletal Diseases [C05]
Digestive System Diseases [C06]
Stomatognathic Diseases [C07]
Respiratory Tract Diseases [C08]
Otorhinolaryngologic Diseases [C09]
Nervous System Diseases [C10]
Eye Diseases [C11]
Male Urogenital Diseases [C12]
Female Urogenital Diseases and Pregnancy Complications [C13]
Cardiovascular Diseases [C14]
Hemic and Lymphatic Diseases [C15]
Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
Skin and Connective Tissue Diseases [C17]
Nutritional and Metabolic Diseases [C18]
Endocrine System Diseases [C19]
Immune System Diseases [C20]
Disorders of Environmental Origin [C21]
Animal Diseases [C22]
Pathological Conditions, Signs and Symptoms [C23]
Available at: http://www.nlm.nih.gov/mesh/trees.html
doi:10.1371/journal.pone.0033677.t002
Table 3. Frequency of intermediate terms and top node
terms that did not match annotations of lower-level terms.
Specialty n/N (%)
Cardiology 172/5264 (3.3%)
Oncology 284/5264 (5.4%)
Mental health 93/5264 (1.8%)
n=number of intermediate- and top-node MeSH terms for a given specialty
that do not match the annotations of their lower-level terms. N=total number
of intermediate- and top-node MeSH terms.
doi:10.1371/journal.pone.0033677.t003
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following steps: 1) study records are checked for the presence of a
MeSH term, including synonyms and lexical variations; 2)
weighted scores are computed for all matches, with exact
matches, lexical variations, and synonyms receiving descending
proportional weight; 3) very common terms are excluded to avoid
confounding; 4) location by data element is considered and
weighted in the term scoring process; and 5) terms with scores
exceeding the cutoff value are applied to the respective studies.
(Note that the output from steps 1 and 2 is used for both condition
and intervention annotations; the field weights are different for
each and divert terms into the target annotation type.) This
method does not consider the natural-language context for
matched terms or ontologically related concepts that would add
specificity. Neither the terms from data submitters nor the NLM
algorithm attempt to associate a term with a particular MeSH
hierarchy. These resulting annotated MeSH terms are visible on
the ClinicalTrials.gov website and populated in the condition_browse
and intervention_browse fields in the downloaded XML file for each
study. Figure 4 illustrates how MeSH terms are created in the
ClinicalTrials.gov database.
2.2. MeSH Disease Conditions Annotation. Condition
and intervention terms in the MeSH thesaurus are arrayed in
hierarchical branching structures, called trees; each branching
point is referred to as a node. Nodes range from 1 (highest level) to
12 (lowest level) in the 2010 version of the MeSH thesaurus. For
example, one high-level category that we used to classify studies by
clinical specialty was Diseases. In the 2010 MeSH thesaurus, this
category contains 23 subcategories (Table 2).
In order to create specialty datasets from the larger AACT
dataset, we selected four high-level MeSH nodes from the
thesaurus to serve as an initial basis for identifying studies by
clinical specialty. Reviewers with relevant subject matter expertise
annotated MeSH terms from the following high-level nodes: 1)
Diseases;2 )Analytical, Diagnostic and Therapeutic Techniques and
Equipment;3 )Psychiatry and Psychology; and 4) Phenomena and Processes.
A total of 18,491MeSH IDs associated with 9031 MeSH terms
were reviewed and annotated by clinical specialists belonging to
one of the 13 clinical specialties and five sub-specialties, which
were selected on the basis of availability of faculty representation
and volunteers at Duke, as well as intention to analyze subsets of
data by clinical specialty. Participating specialty annotations
Figure 5. MeSH trees for acromegaly. Source: 2010 online MeSH thesaurus (available: http://www.nlm.nih.gov/cgi/mesh/2010/MB_cgi).
doi:10.1371/journal.pone.0033677.g005
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ogy, immunology/ rheumatology, infectious diseases, mental
health, nephrology, neurology, oncology, otolaryngology, pulmo-
nary medicine, reproductive medicine, while subspecialty anno-
tations included peripheral vascular disease, peripheral arterial
disease, diabetes, thyroid disease, and bone disease. The
association of terms with clinical specialties was performed in
the context of the anticipated analysis of the data subset for
respective specialties. The results of this extension to the AACT
database, including specialty tags, will be shared in future
publications.
2.3. Validation of Inconsistently Annotated MeSH Terms
and Limitations of Using the MeSH Hierarchy. A term
occurring at a particular node ‘‘node x’’ (parent) may have several
branches (children) at node x+1 that provide a finer classification
of the node-x term. Clinical specialists were advised to review the
hierarchy of an individual MeSH term during the annotation
process. Annotated MeSH descriptors were programmatically
reviewed for hierarchical inconsistencies in order to maintain the
logical relationship between parent and child MeSH descriptors.
Tag validity was evaluated by a process based on annotation rules.
In general, selection or negation of a parent MeSH term should
match with all subsequent child MeSH terms below that node.
Hierarchical inconsistencies in MeSH annotations were flagged
and accepted after further review and confirmation by clinical
specialists. The anticipated inconsistency of the MeSH
hierarchical structure with clinical specialty groupings was
confirmed in the validation process. Table 3 shows the
frequency of parent terms that did not match with annotations
for their children terms.
Further, a term might appear within more than one tree. For
example, the MeSH term Acromegaly appears as part of multiple
trees within the topmost MeSH hierarchical category of Diseases
(Figure 5).
Depending on its hierarchical location, its context could fall
under Musculoskeletal Diseases, Nervous System Diseases,o rEndocrine
System Diseases. Unfortunately, there currently is no way to
differentiate among different tree numbers (MeSH IDs) for the
same MeSH term. If a study contained the term Acromegaly, the
three associated MeSH IDs could have conflicting tags (e.g., No,
No, Yes) for a given specialty. This might result in erroneously
including this study in a particular specialty dataset. As an
additional validation check, all MeSH terms that had conflicting
tags, as in the example above, were flagged and allowed to be
adjudicated by clinical specialists.
Tagging was summarized by MeSH term. For a given MeSH
term, if all MeSH IDs had a Y tag (‘‘yes’’ or ‘‘true’’), then the
MeSH term was given a Y; if all MeSH IDs had an N tag (‘‘no’’
or ‘‘false’’), then the MeSH term was given a N tag; and if there
was a mix of Y and N tags the term was given an A tag
(‘‘ambiguous’’).
2.4. Free-text Disease Conditions (non-MeSH condition
terms): Annotation and Validation. In order to ascertain the
condition being investigated in a given study, we also used the free-
text condition terms provided by data submitters. These terms are
Table 4. Number of studies reviewed by each set of clinician
reviewers.
Reviewer A ID Reviewer B ID Studies reviewed (n)
Clinician 1 Clinician 2 200
Clinician 1 Clinician 3 400*
Clinician 4 Clinician 5 200
Clinician 6 Clinician 7 200
*The combination of Clinician 1 (‘‘A’’) and Clinician 3 (‘‘B’’) together reviewed 2
batches of studies.
doi:10.1371/journal.pone.0033677.t004
Figure 6. Rules for deciding whether a given study belongs to a given specialty.
doi:10.1371/journal.pone.0033677.g006
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Condition field in the downloaded XML file for each study. Non-
MeSH condition terms that appeared in five or more studies were
also selected for specialty classification from interventional studies
registered after September 27, 2007 (n=40,970). These terms
were reviewed by two independent clinicians from each relevant
specialty; disagreements were adjudicated by a third independent
reviewer.
We elected to use both MeSH and non-MeSH disease condition
terms for the following reasons: first, over 10% of studies do not
have condition_browse mesh_terms; second, common terms may be
excluded from the condition_browse mesh_terms annotation; and
third, because of the potential for duplication or mismatch
described above, reliance on indexing by MeSH term alone does
not suffice for re-grouping studies in ClinicalTrials.gov by clinical
specialty.
2.5. Algorithm for Classifying Clinical Discipline. We
used a combination of rules representing disease conditions and
MeSH terms for classifying clinical specialty within interventional
studies. We only included trials registered with ClinicalTrials.gov
after September 27, 2007. The final list of annotated disease
condition terms (MeSH and free-text) was used as a lookup table
to create study datasets for individual specialties.
For each specialty, studies were grouped according to the
following rules (Figure 6):
Group 1: Include a study in this group if any of its MeSH terms
from the CONDITION_BROWSE table or condition terms were
annotated with a Y (‘‘yes’’ or ‘‘true’’) for the specialty.
Table 5. Contingency table for identifying misclassification errors.
Algorithm
Yes (Y) No (N) Ambiguous Unclassified Total
Manual review Yes (Y) A B GHA +B+G+H
No (N) C DI J C +D+I+J
Unknown E F K L E+F+K+L
Total A+C+EB +D+FG +I+KH +J+LT
The overall misclassification error rate divides the total number of errors by the total number of studies reviewed. The false positive rate was determined using two
methods: in the first, the false-positive rate was calculated among studies classified as N by manual review; in the second, the false-positive rate was calculated among
studies classified as Y by the algorithm. The false-negative rate was evaluated in similar fashion: by dividing the number of false negatives by the number of studies
classified as Y by manual review, or by the number of studies classified as N by the algorithm.
doi:10.1371/journal.pone.0033677.t005
Table 6. Classification of studies: algorithmically vs. manually.
CARDIOLOGY
Algorithm
N Y Ambiguous Unclassified Total
N 836 18 1 49 904
Manual review Y2 1 7 2 0 2 9 5
Unknown 1 0 0 0 1
Total 858 90 1 51 1,000
ONCOLOGY
Algorithm
N Y Ambiguous Unclassified Total
N 700 4 1 49 754
Manual review Y 7 237 0 2 246
Unknown 0 0 0 0 0
Total 707 241 1 51 1,000
MENTAL HEALTH
Algorithm
N Y Ambiguous Unclassified Total
N 838 21 8 51 918
Manual review Y1 0 7 2 0 0 8 2
Unknown 0 0 0 0 0
Total 848 93 8 51 1,000
doi:10.1371/journal.pone.0033677.t006
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and b) any of its MeSH terms from the CONDITION_BROWSE
table or condition terms were annotated with an A (‘‘ambiguous’’)
for the specialty.
Group 3: Include a study in this group if a) it is not in Groups 1
or 2, and b) all of its MeSH terms from the CONDITION_
BROWSE table and all of its condition terms were annotated with
an N (‘‘no’’ or ‘‘false’’) for the specialty.
Group 4: Include a study in this group if a) it is not in Groups 1,
2. or 3, and b) any of its MeSH terms from the CONDITION_
BROWSE table or any of its condition terms were annotated with
an N (‘‘no’’ or ‘‘false’’) for the specialty.
Group 5: Include all studies in this group that are not in Groups
1, 2, 3, or 4.
For the validation results reported in this manuscript, the
cardiology, oncology, and mental health groups correspond to
Group 1. A single study could be classified as belonging to multiple
clinical disciplines. For the validation results reported below,
studies in Groups 3 and 4 were pooled and correspond to studies
not classified as not-cardiology, not-oncology, and not-mental
health, respectively. For purposes of investigations focused on each
respective clinical specialty, Groups 1 and 2 were pooled. Based on
custom inclusion/exclusion criteria for these investigations, some
of these studies were excluded from the final specialty datasets.
A different method was used to identify relevant studies for the
specialties of genomics and pediatrics. For the genomics dataset,
observational studies were also included, and condition fields,
intervention fields, and other relevant fields were searched for
terms such as ‘‘gene,’’ ‘‘genomic,’’ and ‘‘DNA.’’ Pediatric studies
were defined as those that restricted enrollment to a pediatric
population (i.e., maximum age of 18 years). The identification of
the sets of genomics and pediatrics studies has not been validated
by the methods described in the following section.
3. Quality Assessment of Specialty Classification System
Using Cardiology, Mental Health, and Oncology Datasets
We evaluated the accuracy of the classification algorithm
described above by comparing it with classifications provided by
expert clinical review of classifications for cardiology, oncology,
and mental health trials. These three specialties were chosen
because together they represent approximately 39% (15,907) of all
interventional trials (n=40,970) registered in the ClinicalTrials.
gov registry from September 27, 2007 to September 27, 2010. The
expert review was performed to ensure that the allocation of
studies into clinical domains would be valid for the intended
analysis purpose of quantifying the distribution of studies by
clinical discipline and describing and comparing the characteristics
of studies across specialties.
3.1. Manual Study Classification. To estimate
misclassification rates for disease specialty classifications, a
random sample of 1000 interventional studies registered with
ClinicalTrials.gov within the relevant time period was selected
from the clinical specialty datasets. The brief title, brief
description, keywords, and study conditions were provided to a
group of seven clinical specialists, who were also given a link to the
full record in ClinicalTrials.gov if they needed more information
to classify the study. The 1000-study sample was divided into
batches of 200 studies. Each batch was reviewed by two clinical
specialists (designated ‘‘A’’ or ‘‘B’’ for that particular batch; see
Table 4) who indicated ‘‘yes,’’ ‘‘no,’’ or ‘‘unknown’’ for each study
within the cardiology, oncology, and mental health classifications,
respectively. Disagreements between reviewers were adjudicated
by an independent eighth reviewer. Adjudicated results were
compared with the specialty datasets to determine misclassification
rates.
Table 7. Comparison between manual classification and algorithmic classification for cardiology, oncology, and mental health.
Cardiology Oncology Mental Health
% Specialty by manual review 9.5% 24.6% 8.2%
% Specialty by algorithm* 9.5% 25.4% 9.9%
False positives{
Among studies classified as N by manual review 2.0% 0.5% 2.3%
Among studies classified as Y by algorithm 20.0% 1.7% 22.6%
False negatives{
Among studies classified as Y by manual review 22.1% 2.8% 12.2%
Among studies classified as N by algorithm 2.4% 1.0% 1.2%
Overall incorrectly classified studies 4.2% 1.2% 3.3%
Overall ambiguous studies 0.1% 0.1% 0.8%
Overall unclassified studies 5.1% 5.1% 5.1%
*Excluding unclassified & ambiguous from denominator.
{Studies that were incorrectly included in a given specialty (e.g. non-cardiology studies classified as cardiology).
{Studies that were incorrectly excluded from a given specialty (e.g. cardiology studies classified as non-cardiology).
doi:10.1371/journal.pone.0033677.t007
Table 8. Summary of disagreements between clinical
specialty reviewers in study classification.
Disagreement* n/N (%)
Reviewers A&B Cardiology Oncology Mental health
Reviewers 1 & 2 12/200 (6.0%) 9/200 (4.5%) 16/200 (8.0%)
Reviewers 1 & 3 20/400 (5.0%) 6/400 (1.5%) 18/400 (4.5%)
Reviewers 4 & 5 18/200 (9.0%) 11/200 (5.5%) 14/200 (7.0%)
Reviewers 6 & 7 18/200 (9.0%) 9/200 (4.5%) 18/200 (9.0%)
Overall 68/1,000 (6.8%) 35/1,000 (3.5%) 66/1,000 (6.6%)
*Defined as any difference in classification of a study by the two reviewers of
that study.
doi:10.1371/journal.pone.0033677.t008
Database for Aggregate Analysis of CT.gov
PLoS ONE | www.plosone.org 10 March 2012 | Volume 7 | Issue 3 | e336773.2. Estimation of Misclassification Errors. We used the
algorithm described in the previous section to determine the
predicted clinical domain for each study in the random sample
(e.g., ‘‘yes’’ or ‘‘no’’ for cardiology), which was compared against
the classification provided by the adjudicated expert review
(Table 5). The studies in each cell of Table 5 were counted and
the results for each clinical domain were considered in-
dependently. Two types of misclassification errors were con-
sidered. A false positive error is made if the algorithm classifies a
study as Y (‘‘Yes’’) but in truth the study is an N (‘‘No’’). The ‘‘C’’
cell in indicates the false positive errors. A false negative error is
made if the algorithm classifies a study as N but in truth the study is
a Y. The ‘‘B’’ cell indicates the false negative errors.
3.3. Sampling Approach and Required Sample
Size. Several factors informed our decision to select a sample
size of approximately 1000 studies. First, if the true rate of mis-
classification was relatively low, we would need a correspondingly
large number of studies to detect misclassifications. Second,
because the precision of the estimate of the error rate increases
with the sample size, we selected a sample size likely to provide
reasonable precision. Third and finally, in order to ensure
sufficient representation from each clinical domain, we needed
to sample a large number of studies from the overall database (e.g.,
cardiology was expected to comprise ,10% of the total database).
3.4. Comparisons of Algorithmic Classification with
Manual Classification. Classification of sampled studies by
manual review as cardiology, oncology, or mental health was
compared with classification by algorithm. Table 6 shows the
comparisons for manual vs. algorithmic classification for
cardiology, oncology, and mental health. The results of
comparisons are summarized in Table 7. Rates of disagreement
between clinical reviewers are presented in Table 8.
3.5. Evaluating Use of NLM-generated MeSH Terms in
Addition to Disease Condition Terms for Specialty
Classification. As described above, specialty classification
uses data from two fields: the condition field, which contains the
disease conditions provided by the data submitter and
accommodates a combination of MeSH and non-MeSH terms;
and the condition_browse field, which contains only MeSH terms
generated by the NLM algorithm. To evaluate the reliability of
using condition_browse for classifying studies into specialty groups,
we compared study datasets created using only NLM-generated
MeSH disease condition terms with those created using only
submitted conditions. We used cardiology, oncology, and mental
health annotations to perform comparisons between methods and
found that the differences were within 4.9% for these specialty
datasets (cardiology within 1.1%; oncology within 2.5%; mental
health 4.9%). Table 9 shows a comparative analysis using two
sources (condition and condition_browse).
Results and Discussion
To our knowledge, the present study represents the first report
of an attempt to create and maintain a version of ClinicalTrials.-
gov data for aggregate analysis and public use of the data—
undertakings that constitute a significant enhancement of the
ClinicalTrials.gov database. Specifically, we have described the
procurement and generation of an integrated database; the parsing
of the database’s Study Design variable into a format that can be
used for analysis; the creation of a change history in the underlying
data element definitions; and the display of basic trends in data
quality metrics.
Our novel system for classifying studies by clinical specialty is a
result of combining technology with medical subject matter
expertise, based on extensive data curation that incorporates
coding by physicians representing relevant clinical specialties, as
well as use of MeSH taxonomy and submitted disease conditions.
Applying this methodology to complete a taxonomy by clinical
specialty would facilitate policy-oriented investigations, such as 1)
future research policy studies aimed at evaluating disparities in the
geographical distribution of clinical trials and of biomedical
research literature in relation to the local burden of diseases [15];
Table 9. Summary of results of comparison between condition_browse and condition data by specialty classification.
Cardiovascular Oncology Mental health
Condition browse Condition Condition browse Condition Condition browse Condition
% Specialty by manual review 9.5% 9.5% 24.6% 24.6% 8.2% 8.2%
% Specialty by algorithm* 8.6% 9.1% 27.3% 24.8% 8.3% 9.1%
False positives{
Among studies classified as
N by manual review
1.4% 1.5% 0.4% 0.3% 1.2% 1.5%
Among studies classified as
Y by algorithm
17.8% 18.2% 1.3% 0.9% 15.9% 18%
False negatives{
Among studies classified as
Y by manual review
23.2% 22.1% 2.8% 4.5% 8.5% 13.4%
Among studies classified as
N by algorithm
2.8% 2.7% 1.7% 1.7% 1.4% 1.4%
Overall incorrectly classified
studies
4.1% 4.2% 1.2% 1.5% 2.2% 3.0%
Overall ambiguous studies 0.0% 0.1% 0.3% 0.0% 1.5% 0.8%
Overall unclassified studies 15.5% 14.9% 15.5% 14.9% 15.5% 14.9%
*excluding unclassified & ambiguous from denominator.
{Studies that were incorrectly included in a given specialty (e.g., non-cardiology studies classified as cardiology).
{Studies that were incorrectly excluded from a given specialty (e.g., cardiology studies classified as non-cardiology).
doi:10.1371/journal.pone.0033677.t009
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publications over time by clinical specialties [16]; 3) the
progression of interdisciplinarity in medical specialties (by
examining the degree of overlap in MeSH terms over time); and
4) the comparative distribution of evidence levels across specialties,
focusing on areas historically characterized by low levels of
evidence. Each of these topics is crucial, not only for ensuring
alignment between regional and global healthcare needs, but also
for defining evidence-based strategic plans in relation to national
and regional biomedical research policies.
Despite the significant value provided by the AACT, this
resource has limitations. First, ClinicalTrials.gov was primarily
intended to serve as a public data repository and was not designed
to support aggregate analysis. Second, the original MeSH
classification was not created to accommodate hierarchical
arrangement of clinical specialties and a given condition may be
stored in multiple locations. Because the current MeSH structure
does not allow differentiation among clinical specialties, false
positive results may occur when attempting to query the database
for a given condition. Third, because the methodology developed
to annotate the AACT database by clinical specialty relied on a
group of experts exclusively from Duke University, further
validation would be appropriate. Fourth, the process for curation
and development of the taxonomy were both time- and resource-
intensive. For this reason, further investigation should explore
methods for streamlining this process, potentially distributed
across a large, open curation community. Fifth, the use of
standard ontologies and vocabularies from all clinical disciplines
would be ideal for encompassing a complete specialty classifica-
tion. Sixth and finally, while we believe that our study classification
methodologies have the potential to facilitate policy-oriented
investigations, the usefulness of our approach in these arenas will
need to be confirmed by more formal validation processes.
Future development for this database could expand into a
number of areas. First, the curated database and, when completed,
the accompanying clinical specialty taxonomy, could be repre-
sented using the Resource Description Framework (RDF) [17] to
enable merging with the linkedCT [9] version of the Clinical-
Trials.gov dataset and other RDF resources. Second, possible
additions to the database include the standardization of sponsor
lists, interventions, outcome measures, universities, and the
connection to geolocation datasets such as GeoNames [18].
Importantly, future additions should be driven by the value they
might provide to research policy makers [19], ultimately
improving the quality of biomedical research and, consequently,
the healthcare delivered to patients.
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